Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
Narrows Institute for Biomedical Research · with Sun Pharmaceutical Industries Limited · NCT06952517
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 2
- Target enrollment
- 20
- US sites recruiting
- 1
- Study start
- March 14, 2025
- Record last updated
- May 6, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Being studied: Clascoterone Cream 1%
Conditions: Papular-pustular Rosacea; Papulopustular Rosacea (PPR); Papulopustular Rosacea
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Men and women ages 18+.
- Diagnosis of rosacea type 2 (papulopustular).
- Available and willing to comply with study instructions and attend all study visits.
- Able and willing to provide written and verbal informed consent.
- Subject has used the same type and brand of make-up, other facial products, and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the baseline visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.
Exclusion Criteria
- Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
- Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
- Pregnant, lactating, or is planning to become pregnant during the study.
- Subject is currently enrolled in an investigational drug or device study.
- Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (baseline).
- Study participant has facial hair that could interfere with the study assessments in the opinion of the investigator.
- Study participant is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
- Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.
- Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.
Recruiting US locations
New York Harbor VA Brooklyn Campus
Brooklyn, NY 11209
Site contact: Kayla Zafar, BA · 718-836-6600 · kayla.zafar@va.gov
Study contacts (from the official record)
- Kayla N Zafar, BA · 718-836-6600 · kayla.zafar@va.gov
Similar studies in New York
All dermatology studies in New York →- RecruitingHealthy volunteersPhase 1
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Bambusa Therapeutics
- Location
- New York, NY + 2 other US sites
- Eligibility basics
- Ages 18–72
- RecruitingHealthy volunteers
Clinical Study to Evaluate the Improvement in Hair Loss in Skin of Color Treated With Fractional Non-Ablative Laser
Lumenis Be Ltd.
- Location
- New York, NY
- Eligibility basics
- Ages 21–55
- RecruitingHealthy volunteers
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
Pfizer
- Location
- New York, NY
- Eligibility basics
- Ages 0 mo+ · Women only
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- New York, NY + 22 other US sites
- Eligibility basics
- Ages 18+